About Eligo Bioscience

Eligo Bioscience was founded in May 2014 by scientists and professors from the Rockefeller University (David Bikard & Luciano Marraffini) and the Massachusetts Institute of Technology (Xavier Duportet & Timothy Lu).

After winning several startup competitions, the company has recently raised a €2.4M seed-funding round and has settled its headquarters within the Pasteur Institute in the heart of Paris.

Meet our team

Dr. Xavier Duportet

Dr. Xavier Duportet

CEO & Chairman
Dr. David Bikard

Dr. David Bikard

CSO & Board Member
Dr. Jean-Pierre Lehner

Dr. Jean-Pierre Lehner

Board Member
Dr. Sébastien Groyer

Dr. Sébastien Groyer

Board Member
Sébastien Enault

Sébastien Enault

Head of Business Development
Dr. Antoine Decrulle

Dr. Antoine Decrulle

Synthetic Biologist
Dr. Matthieu Galtier

Dr. Matthieu Galtier

In-Vivo Models Scientist
Erica Lieberman

Erica Lieberman

Synthetic Biologist
Dr. Jesus Fernandez

Dr. Jesus Fernandez

Synthetic Biologist
Prof. Timothy Lu

Prof. Timothy Lu

Advisor & Cofounder
Prof. Luciano Marraffini

Prof. Luciano Marraffini

Advisor & Cofounder
Nathalie Lenfent

Nathalie Lenfent

Executive Assistant
Bertrand Lellouche

Bertrand Lellouche

Chief Financial Officer

Meet our investors

With over €600m in assets under management as of the end of 2015, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, in France and Germany, and in the life sciences field across Europe and North America.

In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.

XavierCompany